Icon, a global CRO power, forecast revenues for 2022 to fall within a range of $7.7 billion to $8.05 billion, which equates to growth of between 43% to 46% versus 2021 numbers. The company said ...
The PRA acquisition deal is a combination of cash and stock. According to terms announced Wednesday, PRA shareholders will receive $80 cash for each share of PRA that they own, plus 0.4125 shares in ...
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has received positive recognition from leading business and industry ...
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries ...
Clinical research organisation (CRO) Icon has begun the integration of Medidata Clinical Data Studio into its clinical studies. This development makes Icon the first CRO to completely integrate this ...
ICON has agreed to acquire PRA Health Sciences for approximately $12 billion in cash and stock, the companies said, in a deal that continues the consolidation of contract research organizations (CROs) ...
Outstanding stock certificates are not affected by the ticker symbol change and do not need to be exchanged. About Trump Media Group CRO Strategy Trump Media Group CRO Strategy is committed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results